Autopsy report · NCT05100251

Clinical Trial of WBC100 on Advanced Solid Tumor

“sponsor's decision to change development strategy (the QOD cohort was completed).”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 years 1 month before it stopped.
• 68 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Zhejiang University

Sponsor type

University, hospital or other

Conditions

Solid Tumor

Interventions

WBC100 QOD; WBC100 QD; WBC100 BID

Participants

68

Sites

1

Countries

China

Trials that died the same way

• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
  “Sponsor decision:Change the Development plan” (71% match in meaning)
• A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
  “Sponsor's clinical development strategy adjustment” (69% match in meaning)
• A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
  “The sponsor adjusts the clinical development strategy.” (67% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (67% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.